Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma.

Robert J Motzer Toni K Choueiri David F McDermott Thomas Powles Yann-Alexandre VanoSaurabh GuptaJin YaoCeline HanRon Ammar Simon Papillon-CavanaghShruti S SaggiM Brent McHenry Petra Ross-MacDonald Megan Wind-Rotolo

Published in: Journal for immunotherapy of cancer (2022)

The exploratory analyses reveal relationships between molecular biomarkers and provide supportive data on how the inflammation status of the tumor microenvironment may be important for identifying predictive biomarkers of response and survival with combination immunotherapy in patients with RCC. Further validation may help to provide biomarker-driven precision treatment for patients with RCC.

Keyphrases

renal cell carcinoma
oxidative stress
electronic health record
genome wide
single cell
single molecule
combination therapy
data analysis
replacement therapy